224 related articles for article (PubMed ID: 29505179)
1. Adverse Gestational Outcomes Associated With Attention-Deficit/Hyperactivity Disorder Medication Exposure During Pregnancy.
Andrade C
J Clin Psychiatry; 2018; 79(1):. PubMed ID: 29505179
[TBL] [Abstract][Full Text] [Related]
2. Placental Complications Associated With Psychostimulant Use in Pregnancy.
Cohen JM; Hernández-Díaz S; Bateman BT; Park Y; Desai RJ; Gray KJ; Patorno E; Mogun H; Huybrechts KF
Obstet Gynecol; 2017 Dec; 130(6):1192-1201. PubMed ID: 29112657
[TBL] [Abstract][Full Text] [Related]
3. Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.
Eiland LS; Bell EA; Erramouspe J
Ann Pharmacother; 2014 Oct; 48(10):1350-5. PubMed ID: 24982313
[TBL] [Abstract][Full Text] [Related]
4. Exposure to attention deficit hyperactivity disorder medications during pregnancy.
Humphreys C; Garcia-Bournissen F; Ito S; Koren G
Can Fam Physician; 2007 Jul; 53(7):1153-5. PubMed ID: 17872810
[TBL] [Abstract][Full Text] [Related]
5. Association Between Methylphenidate and Amphetamine Use in Pregnancy and Risk of Congenital Malformations: A Cohort Study From the International Pregnancy Safety Study Consortium.
Huybrechts KF; Bröms G; Christensen LB; Einarsdóttir K; Engeland A; Furu K; Gissler M; Hernandez-Diaz S; Karlsson P; Karlstad Ø; Kieler H; Lahesmaa-Korpinen AM; Mogun H; Nørgaard M; Reutfors J; Sørensen HT; Zoega H; Bateman BT
JAMA Psychiatry; 2018 Feb; 75(2):167-175. PubMed ID: 29238795
[TBL] [Abstract][Full Text] [Related]
6. Risk of Major Congenital Malformations Associated With the Use of Methylphenidate or Amphetamines in Pregnancy.
Andrade C
J Clin Psychiatry; 2018; 79(1):. PubMed ID: 29370484
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis.
Elliott J; Johnston A; Husereau D; Kelly SE; Eagles C; Charach A; Hsieh SC; Bai Z; Hossain A; Skidmore B; Tsakonas E; Chojecki D; Mamdani M; Wells GA
PLoS One; 2020; 15(10):e0240584. PubMed ID: 33085721
[TBL] [Abstract][Full Text] [Related]
8. Treatment with psychostimulants and atomoxetine in people with psychotic disorders: reassessing the risk of clinical deterioration in a real-world setting.
Corbeil O; Brodeur S; Courteau J; Béchard L; Huot-Lavoie M; Angelopoulos E; Di Stefano S; Marrone E; Vanasse A; Fleury MJ; Stip E; Lesage A; Joober R; Demers MF; Roy MA
Br J Psychiatry; 2024 Mar; 224(3):98-105. PubMed ID: 38044665
[TBL] [Abstract][Full Text] [Related]
9. Psychosis with use of amphetamine drugs, methylphenidate and atomoxetine in adolescent and adults.
Hamard J; Rousseau V; Durrieu G; Garcia P; Yrondi A; Sommet A; Revet A; Montastruc F
BMJ Ment Health; 2024 Apr; 27(1):. PubMed ID: 38609318
[TBL] [Abstract][Full Text] [Related]
10. Prescription Stimulant Use During Pregnancy and Risk of Neurodevelopmental Disorders in Children.
Suarez EA; Bateman BT; Hernandez-Diaz S; Straub L; McDougle CJ; Wisner KL; Gray KJ; Pennell PB; Lester B; Zhu Y; Mogun H; Huybrechts KF
JAMA Psychiatry; 2024 May; 81(5):477-488. PubMed ID: 38265792
[TBL] [Abstract][Full Text] [Related]
11. Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry.
Cortese S; Panei P; Arcieri R; Germinario EA; Capuano A; Margari L; Chiarotti F; Curatolo P
CNS Drugs; 2015; 29(10):865-77. PubMed ID: 26293742
[TBL] [Abstract][Full Text] [Related]
12. Adverse Drug Reactions Related to Mood and Emotion in Pediatric Patients Treated for Attention Deficit/Hyperactivity Disorder: A Comparative Analysis of the US Food and Drug Administration Adverse Event Reporting System Database.
Pozzi M; Carnovale C; Mazhar F; Peeters GGAM; Gentili M; Nobile M; Radice S; Clementi E
J Clin Psychopharmacol; 2019; 39(4):386-392. PubMed ID: 31205193
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder.
Stiefel G; Besag FM
Drug Saf; 2010 Oct; 33(10):821-42. PubMed ID: 20812768
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder: an update.
Awudu GA; Besag FM
Drug Saf; 2014 Sep; 37(9):661-76. PubMed ID: 25124483
[TBL] [Abstract][Full Text] [Related]
15. [The medical treatment of attention deficit hyperactivity disorder (ADHD) with amphetamines in children and adolescents].
Frölich J; Banaschewski T; Spanagel R; Döpfner M; Lehmkuhl G
Z Kinder Jugendpsychiatr Psychother; 2012 Sep; 40(5):287-99; quiz 299-300. PubMed ID: 22869222
[TBL] [Abstract][Full Text] [Related]
16. Impact of a restrictive drug access program on the risk of cardiovascular encounters in children exposed to ADHD medications.
Guertin J; LeLorier J; Durand M; Gow R; Holbrook A; Levine M
J Popul Ther Clin Pharmacol; 2014; 21(3):e357-69. PubMed ID: 25326915
[TBL] [Abstract][Full Text] [Related]
17. Headache in ADHD as comorbidity and a side effect of medications: a systematic review and meta-analysis.
Pan PY; Jonsson U; Şahpazoğlu Çakmak SS; Häge A; Hohmann S; Nobel Norrman H; Buitelaar JK; Banaschewski T; Cortese S; Coghill D; Bölte S
Psychol Med; 2022 Jan; 52(1):14-25. PubMed ID: 34635194
[TBL] [Abstract][Full Text] [Related]
18. Maternal and neonatal outcomes after exposure to ADHD medication during pregnancy: A systematic review and meta-analysis.
Jiang HY; Zhang X; Jiang CM; Fu HB
Pharmacoepidemiol Drug Saf; 2019 Mar; 28(3):288-295. PubMed ID: 30585374
[TBL] [Abstract][Full Text] [Related]
19. Current pharmacotherapy of attention deficit hyperactivity disorder.
Reddy DS
Drugs Today (Barc); 2013 Oct; 49(10):647-65. PubMed ID: 24191257
[TBL] [Abstract][Full Text] [Related]
20. Caregiver survey of pharmacotherapy to treat attention deficit/hyperactivity disorder in individuals with Williams syndrome.
Martens MA; Seyfer DL; Andridge RR; Foster JE; McClure KE; Coury DL
Res Dev Disabil; 2013 May; 34(5):1700-9. PubMed ID: 23500164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
